Cardiovascular complications contribute to adverse outcomes in patients with influenza and SARS-CoV-2 infections. While the association of RSV infection with cardiovascular events (CVE) has been described, data are limited.

The technology provides a universal solution to respiratory viruses, regardless of an individual's immune history – for example, people who do not sufficiently respond to a vaccine, or don't get vaccinated

New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older.

This group will lead the development of a Call to Action to advocate for better access to treatments, in particular COVID- 19.

The majority of RSV infections in young children are managed in primary care, however, the disease burden in this setting remains poorly defined.

A new joint action focusing on tackling chronic respiratory diseases was recently launched. Backed by the EU4Health programme, the 3-year initiative aims to improve lung health across Europe through innovative digital health technologies.

Use these materials to raise awareness about new immunisation products to protect infants in early life from a top cause of severe respiratory infections in children.

ECDC has launched an online platform, RespiCompass, which uses mathematical modelling to simulate respiratory disease dynamics under different scenarios.